A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 10, 2008, Pages 1153-1158

  Heist, Rebecca Suk ^a   Fidias, Panos ^a   Huberman, Mark ^b   Ardman, Blair ^c   Sequist, Lecia V ^a   Temel, Jennifer S ^a   Lynch, Thomas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c LOWELL GENERAL HOSPITAL   (United States)

Author keywords

Bevacizumab; Non small cell lung cancer; Oxaliplatin; Pemetrexed; Previously treated

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CANFOSFAMIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETALOCIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLITIS; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FACE PAIN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WHEEZING; ADENOCARCINOMA; BRAIN TUMOR; LARGE CELL CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE;

EID: 58949092234     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318187273f     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancr J Clin 2007;57:43-66.
2. Schiller JH, Harrington D, Belani C, et al. Comparison of four platinum chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355: 2542-2550.
4. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 2007;25:4743-4750.
5. Sheperd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based therapy. J Clin Oncol 2000;19:2095-2103.
6. Fosella FV, DeVore R, Kerr RN, et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens. J Clin Oncol 2000;18:2354-2362.
7. Hanna N, Sheperd FA, Fossella FV, et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer. J Clin Oncol 2004;22:1589-1597.
8. Sheperd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously-treated non-small cell lung cancer. N Engl J Med 2005;353:123-132.
9. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 1996;2:1855-1865.
10. Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000;18:1193-1202.
11. Soulie P, Garrino C, Bensmaine MA, et al. Antitumor activity of oxaliplatin/cisplatin based combination therapy in cisplatin-refractory germ cell cancer patients. J Cancer Res Clin Oncol 1999;125:707-711.
12. Scagliotti G, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11:690-696.
13. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Presented at the World Federation of Neuro-Oncology Meeting, 2005, P. 91.
14. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
15. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naüive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007;25:18S.
16. Scagliotti G, Purvish P, von Pawel J, et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2(Suppl 4):S306.